Home
Ventyx Biosciences

八月 2026的Ventyx Biosciences市场份额分析

Privacy Policy Updated: April 4, 2022 This Privacy Policy describes the privacy practices of Ventyx Biosciences, Inc. and its subsidiaries (“Ventyx”, “we”, “us” or “our”). Protecting the privacy and security of your personal information is important to Ventyx. This Privacy Policy is designed to help you understand what data Ventyx may collect, how Ventyx uses […]

健康 > 生物科技及制药

域ventyxbio.com

成立年份2018

员工51 - 200

年营收--

Ventyx Biosciences

Ventyx Biosciences（包含公司地区分支机构）

ventyxbio.com

查看更多网站流量和参与度信息

Ventyx Biosciences热门域名的总访问量

了解Ventyx Biosciences市场份额和潜在市场覆盖范围。

过去 3 个月的总访问量

子公司明细

ventyxbio.com--

使用销售情报查看更多信息

Ventyx Biosciences热门域名的平均访问时长

分析Ventyx Biosciences参与度指标。

过去 3 个月的平均访问时长

子公司明细

ventyxbio.com--

使用销售情报查看更多信息

Ventyx Biosciences热门域名的平均页面浏览量

了解Ventyx Biosciences如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。

过去 3 个月的平均页面浏览量

子公司明细

ventyxbio.com--

使用销售情报查看更多信息

Ventyx Biosciences 排名靠前的竞争对手（按域名）

八月 2026的热门相似网站，按亲和力排名

clinicaltrials.gov公司名称ClinicalTrials.gov员工201 - 500总部美国, 北卡罗来纳, Durham年营收$15M - $25M总访问量3M健康 > 其他健康相关

Ventyx Biosciences 采用的主要技术

这些是排名前 Ventyx Biosciences 的顶级域名所使用的网站技术（按行业分列）

小部件 (3)

Twemoji

内容管理系统 (2)

WordPress

电子邮件服务 (2)

Microsoft Exchange Online

移动设备 (2)

Meta Viewport

更多技术

4

查看全部

Ventyx Biosciences 的新闻与信号

借助 Similarweb 销售信号提醒，每当在目标受众之中出现新的机会或威胁时，您都会收到所识别出购买信号的每日更新。

新闻Ventyx Biosciences, Inc. attended event 75th Annual Scientific Session & Expo on Mar 30th '26.On 30 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana, Phase IIa (NCT06771115) trial results were presented for Ventyx Biosciences' VTX3232 (parunoflast), which was evaluated alone or in combination with semaglutide in patients with obesity.

新闻Ventyx Biosciences, Inc. has issues with securities fraud or other unlawful business practices.The investigation concerns whether Ventyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

新闻Ventyx Biosciences, Inc. launched mid-stage data for lead program VTX3232 on Jun 17th '25.The deal announced after Wednesday's market close follows Ventyx's fall release of mid-stage data for lead program VTX3232, a drug in development for treating inflammation that contributes to cardiovascular disease.